159 related articles for article (PubMed ID: 34453076)
1. Development of multiplex digital PCR assays for the detection of PIK3CA mutations in the plasma of metastatic breast cancer patients.
Corné J; Le Du F; Quillien V; Godey F; Robert L; Bourien H; Brunot A; Crouzet L; Perrin C; Lefeuvre-Plesse C; Diéras V; De la Motte Rouge T
Sci Rep; 2021 Aug; 11(1):17316. PubMed ID: 34453076
[TBL] [Abstract][Full Text] [Related]
2. Development and Validation of a Novel Dual-Drop-off ddPCR Assay for the Simultaneous Detection of Ten Hotspots
Stergiopoulou D; Smilkou S; Georgoulias V; Kaklamanis L; Lianidou E; Markou A
Anal Chem; 2023 Sep; 95(37):14068-14076. PubMed ID: 37681347
[TBL] [Abstract][Full Text] [Related]
3. Clinical significance of plasma cell-free DNA mutations in PIK3CA, AKT1, and ESR1 gene according to treatment lines in ER-positive breast cancer.
Takeshita T; Yamamoto Y; Yamamoto-Ibusuki M; Tomiguchi M; Sueta A; Murakami K; Iwase H
Mol Cancer; 2018 Feb; 17(1):67. PubMed ID: 29482551
[TBL] [Abstract][Full Text] [Related]
4. ESR1 and PIK3CA mutational status in serum and plasma from metastatic breast cancer patients: A comparative study.
Takeshita T; Yamamoto Y; Yamamoto-Ibusuki M; Tomiguchi M; Sueta A; Iwase H
Cancer Biomark; 2018; 22(2):345-350. PubMed ID: 29689710
[TBL] [Abstract][Full Text] [Related]
5. An integrated investigation of structural and pathway alteration caused by PIK3CA and TP53 mutations identified in cfDNA of metastatic breast cancer.
R HC; Kumar S U; R G; Naayanan PJ; Sathiyarajeswaren P; Devi MSS; K SS; Doss C GP
J Cell Biochem; 2023 Feb; 124(2):188-204. PubMed ID: 36563059
[TBL] [Abstract][Full Text] [Related]
6. Plasma cell-free tumor DNA, PIK3CA and TP53 mutations predicted inferior endocrine-based treatment outcome in endocrine receptor-positive metastatic breast cancer.
Chen TW; Hsiao W; Dai MS; Lin CH; Chang DY; Chen IC; Wang MY; Chang SH; Huang SM; Cheng AL; Wu KW; Tan KT; Lu YS
Breast Cancer Res Treat; 2023 Oct; 201(3):377-385. PubMed ID: 37344660
[TBL] [Abstract][Full Text] [Related]
7. Outcome and molecular landscape of patients with PIK3CA-mutated metastatic breast cancer.
Mosele F; Stefanovska B; Lusque A; Tran Dien A; Garberis I; Droin N; Le Tourneau C; Sablin MP; Lacroix L; Enrico D; Miran I; Jovelet C; Bièche I; Soria JC; Bertucci F; Bonnefoi H; Campone M; Dalenc F; Bachelot T; Jacquet A; Jimenez M; André F
Ann Oncol; 2020 Mar; 31(3):377-386. PubMed ID: 32067679
[TBL] [Abstract][Full Text] [Related]
8. Frequency and spectrum of PIK3CA somatic mutations in breast cancer.
Martínez-Sáez O; Chic N; Pascual T; Adamo B; Vidal M; González-Farré B; Sanfeliu E; Schettini F; Conte B; Brasó-Maristany F; Rodríguez A; Martínez D; Galván P; Rodríguez AB; Martinez A; Muñoz M; Prat A
Breast Cancer Res; 2020 May; 22(1):45. PubMed ID: 32404150
[TBL] [Abstract][Full Text] [Related]
9. Development of sensitive and robust multiplex digital PCR assays for the detection of ESR1 mutations in the plasma of metastatic breast cancer patients.
Corné J; Quillien V; Callens C; Portois P; Bidard FC; Jeannot E; Godey F; Le Du F; Robert L; Bourien H; Brunot A; Crouzet L; Perrin C; Lefeuvre-Plesse C; Diéras V; de la Motte Rouge T
Clin Chim Acta; 2023 May; 545():117366. PubMed ID: 37105452
[TBL] [Abstract][Full Text] [Related]
10. Frequent detection of PIK3CA mutations in single circulating tumor cells of patients suffering from HER2-negative metastatic breast cancer.
Gasch C; Oldopp T; Mauermann O; Gorges TM; Andreas A; Coith C; Müller V; Fehm T; Janni W; Pantel K; Riethdorf S
Mol Oncol; 2016 Oct; 10(8):1330-43. PubMed ID: 27491860
[TBL] [Abstract][Full Text] [Related]
11. [PIK3CA gene mutations in Chinese women with HR
Wu SF; Wang XF; Liu YY; Xia C; Liang ZY; Zeng X
Zhonghua Bing Li Xue Za Zhi; 2022 Dec; 51(12):1246-1250. PubMed ID: 36480834
[No Abstract] [Full Text] [Related]
12. PIK3CA hotspot mutations p. H1047R and p. H1047L sensitize breast cancer cells to thymoquinone treatment by regulating the PI3K/Akt1 pathway.
Zhou J; Imani S; Shasaltaneh MD; Liu S; Lu T; Fu J
Mol Biol Rep; 2022 Mar; 49(3):1799-1816. PubMed ID: 34816327
[TBL] [Abstract][Full Text] [Related]
13. Multiplexed assays for detection of mutations in PIK3CA.
Board RE; Thelwell NJ; Ravetto PF; Little S; Ranson M; Dive C; Hughes A; Whitcombe D
Clin Chem; 2008 Apr; 54(4):757-60. PubMed ID: 18375489
[TBL] [Abstract][Full Text] [Related]
14. Detection of PIK3CA mutations in circulating free DNA in patients with breast cancer.
Board RE; Wardley AM; Dixon JM; Armstrong AC; Howell S; Renshaw L; Donald E; Greystoke A; Ranson M; Hughes A; Dive C
Breast Cancer Res Treat; 2010 Apr; 120(2):461-7. PubMed ID: 20107891
[TBL] [Abstract][Full Text] [Related]
15. PIK3CA mutations early persistence in cell-free tumor DNA as a negative prognostic factor in metastatic breast cancer patients treated with hormonal therapy.
Jacot W; Dalenc F; Lopez-Crapez E; Chaltiel L; Durigova A; Gros N; Lozano N; Lacaze JL; Pouderoux S; Gladieff L; Romieu G; Roché H; Filleron T; Lamy PJ
Breast Cancer Res Treat; 2019 Oct; 177(3):659-667. PubMed ID: 31297647
[TBL] [Abstract][Full Text] [Related]
16. PIK3CA mutation profiling in patients with breast cancer, using a highly sensitive detection system.
Shimoi T; Hamada A; Yamagishi M; Hirai M; Yoshida M; Nishikawa T; Sudo K; Shimomura A; Noguchi E; Yunokawa M; Yonemori K; Shimizu C; Kinoshita T; Fukuda T; Fujiwara Y; Tamura K
Cancer Sci; 2018 Aug; 109(8):2558-2566. PubMed ID: 29906308
[TBL] [Abstract][Full Text] [Related]
17. Comparison of Three Real-Time PCR Assays for the Detection of PIK3CA Somatic Mutations in Formalin-Fixed Paraffin Embedded Tissues of Patients with Breast Carcinomas.
Lambert A; Salleron J; Lion M; Rouyer M; Lozano N; Leroux A; Merlin JL; Harlé A
Pathol Oncol Res; 2019 Jul; 25(3):1117-1123. PubMed ID: 30426328
[TBL] [Abstract][Full Text] [Related]
18. PIK3CA mutation enrichment and quantitation from blood and tissue.
Keraite I; Alvarez-Garcia V; Garcia-Murillas I; Beaney M; Turner NC; Bartos C; Oikonomidou O; Kersaudy-Kerhoas M; Leslie NR
Sci Rep; 2020 Oct; 10(1):17082. PubMed ID: 33051521
[TBL] [Abstract][Full Text] [Related]
19.
Tang Y; Li J; Xie N; Yang X; Liu L; Wu H; Tian C; He Y; Wang X; He Q; Hu ZY; Ouyang Q
Aging (Albany NY); 2020 Jan; 12(2):1577-1590. PubMed ID: 31980592
[TBL] [Abstract][Full Text] [Related]
20. PIK3CA hotspot mutations in circulating tumor cells and paired circulating tumor DNA in breast cancer: a direct comparison study.
Tzanikou E; Markou A; Politaki E; Koutsopoulos A; Psyrri A; Mavroudis D; Georgoulias V; Lianidou E
Mol Oncol; 2019 Dec; 13(12):2515-2530. PubMed ID: 31254443
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
